Fulvestrant
Progesterone-Receptor Positive Breast Cancer
Explore 13 assets in Progesterone-Receptor Positive Breast Cancer →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04901299CT.gov Fulvestrant + Neratinib In Breast Cancer | — | Withdrawn | — | — | — |
NCT02269670CT.gov Phase II Study of Everolimus Beyond Progression | — | Terminated | — | — | — |
NCT00057941CT.gov Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Progesterone-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fulvestrant (this asset) | Massachusetts General Hospital | P2 | B · 57 |
| Tamoxifen | Jennifer Lee Caswell-Jin | P2 | BB |
| Letrozole | Ruth O'Regan | P2 | BB |
| Cyclophosphamide | University of Washington | P2 | B |
| Nivestim | University of Washington | P2 | B |
| Sargramostim | Fred Hutchinson Cancer Center | P2 | B |
| Trastuzumab | Massachusetts General Hospital | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | B |
+28 more in the Progesterone-Receptor Positive Breast Cancer cohort
Other indications for Fulvestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 69 |
| Invasive Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fulvestrant in Progesterone-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fulvestrant-progesterone-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →